Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.59 USD | +1.46% | +1.18% | +2.24% |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- The company is one of the best yield companies with high dividend expectations.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The firm trades with high earnings multiples: 25.53 times its 2024 earnings per share.
- Based on current prices, the company has particularly high valuation levels.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialized REITs
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.24% | 3.38B | C+ | ||
+14.97% | 61.99B | A- | ||
+0.84% | 20.31B | A- | ||
+0.51% | 14.01B | A | ||
+5.45% | 7.99B | B | ||
-5.80% | 6.14B | B- | ||
+14.32% | 3.63B | C- | ||
+9.16% | 3.22B | C | ||
-6.13% | 3.08B | B+ | ||
+18.32% | 2.87B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SBRA Stock
- Ratings Sabra Health Care REIT, Inc.